Axsome Therapeutics AXSM Balipodect — Business Combination Consideration Transferred1
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationConsiderationTransferred1.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
In the first quarter of 2026, the Company acquired the global rights to balipodect (AXS-20), a selective PDE10A Inhibitor for the treatment of Schizophrenia and other neuropsychiatric conditions, from Takeda Pharmaceutical Company Limited (Takeda), for $10.4 million, inclusive of transaction costs. Takeda is eligible to receive up to $260.0 million in development, regulatory and sales-based milestones and a mid single-digit royalty on potential global net sales of balipodect.
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's balipodect — business combination consideration transferred1?
- Axsome Therapeutics (AXSM) reported balipodect — business combination consideration transferred1 of $10.4M in Q1 2026.
- What does balipodect — business combination consideration transferred1 mean?
- This represents the total fair value of assets, equity interests, or cash transferred by the company to acquire a business or asset related to the Balipodect program. It captures the upfront investment cost required to secure the intellectual property or development rights for this specific CNS therapeutic candidate. This metric is essential for assessing the capital allocation strategy and the initial valuation placed on the acquired asset.
Ask your AI about Axsome Therapeutics's balipodect — business combination consideration transferred1.
Connect your AI assistant and compare it to peers, right in your chat.
